Full-Time

Program Manager

Early Phase Development Solutions

Posted on 10/6/2025

LabCorp

LabCorp

10,001+ employees

Global life sciences R&D services

No salary listed

Molesworth, Huntingdon, UK + 1 more

More locations: Harrogate, UK

Hybrid

Hybrid working model with options for on-site work at either Harrogate or Huntingdon.

Category
Business & Strategy (1)
Required Skills
Risk Management
Requirements
  • BSc in the Life Sciences field or equivalent industry experience
  • Demonstrable client facing experience within pre-clinical field; CRO experience advantageous
  • Strong oral and written communication skills
  • Ability to work to deadlines, prioritize tasks and manage multiple changing priorities
  • Excellent customer service skills with a strong focus on client needs
  • Strong planning and organizational skills
  • Computer proficiency with good working knowledge of a range of I.T packages
  • Ability to work with financial information
  • Capable of working autonomously but also in a team environment acting as a mentor where appropriate
Responsibilities
  • Ensure appropriate commercial documents are in place prior to studies, including CDA's, contracts, and any quality/technical documents with the client and any third party vendors
  • Liaise with the relevant commercial organization team members to ensure post-award handoff, including sharing all documents, timelines and program scope
  • Review and evaluate awarded scope, identify any operational challenges, and suggest solutions
  • Prepare and host kick off meeting with internal study teams and client representatives
  • Set up and lead program debrief after all studies within the development program are completed
  • Responsible for the management and tracking of individual project resources needed throughout the development program. Contribute to contingency planning for key resources and activities
  • Manage third party vendors as necessary, including overseeing milestones and billing/invoicing
  • Engage with key SMEs to provide expert knowledge of Labcorp service lines and capabilities, including sites where work is performed
  • Prepare and maintain the appropriate tools, such as Gantt, study trackers, financial trackers, communication plan, risk log, action trackers, etc. for each program, ensure that they are maintained and the program teams, including the client, are provided with regular updates
  • Independently provide a program management service for low - mid complexity drug development programs to the client including coordination of internal and external teams across multiple Labcorp business units globally; may provide program management service for higher complexity programs with support from a Director Drug Development & Regulatory Strategy DD&RS or a CPC (Crop Protection and Chemical) Regulatory Program Director
  • Lead the core program team, including Study Directors, Principal Investigators, Project Managers from individual business units, and third party vendors for low - mid complexity programs; assist in leading the core team for higher complexity programs with support from a DD&RS or a CPC Regulatory Program Director.
Desired Qualifications
  • CRO experience advantageous

Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Burlington, Vermont

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $3.54B, up 5.8%, raising full-year guidance to $14.73B.
  • AI Alzheimer's platform validates spring 2026, expands to oncology and cardiometabolic areas.
  • Optum.ai partnership automates lab workflows and enhances patient engagement.

What critics are saying

  • Quest Diagnostics outgrows Labcorp at 9.2% versus 5.8%, eroding diagnostics share in 6-12 months.
  • NeoGenomics seizes oncology volume with 11.1% growth, hitting Labcorp's specialty testing now.
  • Tempus commoditizes Labcorp's AI platform with superior EHR integration in 24 months.

What makes LabCorp unique

  • Labcorp's AI platform with AWS and Datavant analyzes Alzheimer's data in minutes using deidentified lab datasets.
  • Labcorp holds first FDA clearance for rapid fentanyl urine test in emergency settings.
  • Labcorp's Plasma Detect Genome MRD assesses NSCLC recurrence risk via whole-genome sequencing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Tuition Reimbursement

Employee Stock Purchase Plan

Company News

360Dx
May 5th, 2026
Fox Chase Cancer Center, Labcorp collaborate on clinical trial for Plasma Detect Genome MRD in NSCLC.

Fox Chase Cancer Center, Labcorp collaborate on clinical trial for Plasma Detect Genome MRD in NSCLC. NEW YORK - Temple Health's Fox Chase Cancer Center and Laboratory Corporation of America announced Tuesday a clinical trial collaboration to evaluate the use of Labcorp's whole-genome sequencing Plasma Detect Genome MRD to assess the risk of recurrence in patients with early stage non-small cell lung cancer (NSCLC). Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Resonate Group
Apr 15th, 2026
Labcorp launches rapid fentanyl test with 48-hour detection window.

Labcorp launches rapid fentanyl test with 48-hour detection window. * April 15, 2026 While fentanyl overdose deaths have been falling in recent years, use of the drug remains a major public health crisis in the U.S., and now Labcorp is launching a new test designed to detect the drug's use for up to 48 hours after exposure. Fields (*) Mark are Required

PR Newswire
Apr 14th, 2026
Labcorp launches AI-powered platform with AWS and Datavant to accelerate Alzheimer's research

Labcorp has launched an AI-powered real-world data platform to accelerate Alzheimer's disease research, developed in collaboration with Amazon Web Services and Datavant. The platform aims to generate insights in minutes that previously required months of data analysis. The system combines Labcorp's diagnostic and genomic datasets with medical claims data, using AWS AI services including Amazon Bedrock and Amazon SageMaker. It enables researchers to identify patient cohorts, track disease progression and measure treatment effectiveness across diverse populations using deidentified healthcare data. With over 7.2 million Americans living with Alzheimer's and annual care costs exceeding $380 billion in the US, the platform addresses traditional challenges of fragmented data and lengthy preparation times. Initial validation will complete in spring 2026, with plans to expand into inflammatory diseases, cardiometabolic conditions, women's health and oncology.

360Dx
Apr 13th, 2026
Labcorp, CHOP to develop, commercialize specialty pediatric diagnostics.

Labcorp, CHOP to develop, commercialize specialty pediatric diagnostics. NEW YORK - Laboratory Corporation of America and Children's Hospital of Philadelphia (CHOP) on Monday announced a strategic collaboration to accelerate the development of and access to specialized pediatric diagnostics. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

360Dx
Mar 20th, 2026
In brief this week: Labcorp, guardant Health, waters, fulgent genetics, more.

In brief this week: Labcorp, guardant Health, waters, fulgent genetics, more. NEW YORK - Laboratory Corporation of America this week said it has completed its acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York's laboratory business. The two firms also have entered into a deal for Crouse Health to manage the daily operations of its inpatient lab, while Labcorp will take over operations of the lab alliance's 12 patient service centers. It said in a statement that the deal will improve access to high-quality, affordable diagnostic services in Central New York by offering patients and providers Labcorp's expanded testing menu, data, and digital tools. To read the full story... What's Popular?

INACTIVE